A -year-old woman presents to the emergency department with a -day history of severe abdominal cramps and frequent, grossly bloody diarrhea. She recalls eating an undercooked hamburger at a picnic days prior. Her temperature is (), blood pressure is , and pulse is . Physical examination reveals diffuse abdominal tenderness without rebound or guarding. Suspecting an infection with enterohemorrhagic \textit{Escherichia coli} (EHEC), arrange the following clinical management steps in the most appropriate chronological order.
- 1Send stool specimens for bacterial culture and Shiga toxin enzyme immunoassay.
- 2Initiate intravenous fluid resuscitation and purposefully withhold empiric antibiotic and antimotility therapies.
- 3Monitor serial complete blood counts, peripheral blood smears, and serum creatinine levels.
- 4Initiate renal replacement therapy (hemodialysis) if refractory anuria and uremia develop.
Cevap
The correct sequence is: 1) Send stool for culture and Shiga toxin assay, 2) Initiate IV fluids and strictly withhold empiric antibiotics, 3) Monitor serial blood counts and renal function for HUS, 4) Initiate hemodialysis if refractory uremia develops.
The correct chronological management of suspected enterohemorrhagic E. coli begins with diagnostic testing (Shiga toxin assay) to confirm the etiology. The immediate therapeutic step is fluid resuscitation while strictly avoiding antibiotics, as their use increases Shiga toxin release and the risk of Hemolytic Uremic Syndrome (HUS). Following initial stabilization, the patient must be monitored with serial blood counts and renal function panels to detect the onset of HUS (thrombocytopenia, hemolytic anemia, acute kidney injury). Finally, if HUS progresses to severe or refractory renal failure, late-stage supportive care with hemodialysis is indicated.
Adım Adım Çözüm
Anahtar Kavram
Management of Shiga toxin-producing E. coli (EHEC) involves avoiding antibiotics to prevent Hemolytic Uremic Syndrome (HUS), utilizing aggressive fluid resuscitation, and monitoring for microangiopathic complications.